Search

Your search keyword '"Bekaii-Saab, Tanios"' showing total 1,737 results
Start Over Author "Bekaii-Saab, Tanios"
1,737 results on '"Bekaii-Saab, Tanios"'

211. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA

Author

Bekaii-Saab, Tanios S., Johnson, Frank E., editor, Maehara, Yoshihiko, editor, Browman, George P., editor, Margenthaler, Julie A., editor, Audisio, Riccardo A., editor, Thompson, John F., editor, Johnson, David Y., editor, Earle, Craig C., editor, and Virgo, Katherine S., editor

Published
2013
Full Text
View/download PDF

213. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study

Author

Grotz, Travis E., primary, Yonkus, Jennifer A., additional, Thiels, Cornelius A., additional, Warner, Susanne G., additional, McWilliams, Robert R., additional, Mahipal, Amit, additional, Bekaii-Saab, Tanios S., additional, Cleary, Sean P., additional, Kendrick, Michael L., additional, and Truty, Mark J., additional

Published
2022
Full Text
View/download PDF

216. MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers

Author

Shitara, Kohei, primary, Park, Haeseong, additional, Bekaii-Saab, Tanios, additional, Kim, Sunnie S., additional, Kamath, Suneel, additional, Pishvaian, Michael J., additional, Chen, Christopher, additional, Zhen, David B., additional, Mayor, Joal, additional, Tan, Qianwen, additional, and Strickler, John H., additional

Published
2022
Full Text
View/download PDF

217. Abstract 6274: Prognostic impact of Sarcopenia on clinical outcomes in advanced hepatocellular carcinoma (HCC) treated with systemic therapy

Author

Botrus, Gehan, primary, Junior, Pedro Luiz Serrano Uson, additional, Kosiorek, Heidi, additional, Akce, Mehmet, additional, Chang, Isabela, additional, Mesbah, Zhubene, additional, Yancey, Eric, additional, Blezek, Daniel, additional, Klug, Jason, additional, Khalil, Lana, additional, Raman, Puneet, additional, Sonbol, Mohamad, additional, Borad, Mitesh, additional, Ahn, Daniel, additional, and Bekaii-Saab, Tanios, additional

Published
2022
Full Text
View/download PDF

218. SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).

Author

Kopetz, Scott, primary, Bekaii-Saab, Tanios S., additional, Yoshino, Takayuki, additional, Chung, Chin-Hee, additional, Zhang, Xiaosong, additional, and Tabernero, Josep, additional

Published
2022
Full Text
View/download PDF

220. IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of imu-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101).

Author

Richardson, Gary Edward, primary, Park, John J., additional, Boyer, Michael J., additional, Gutierrez, Martin, additional, Carbone, David Paul, additional, Savvides, Panayiotis, additional, Kaumaya, Pravin, additional, Bekaii-Saab, Tanios S., additional, Phan, Tri Guang, additional, Chong, Leslie Mi Ok, additional, Cha, Steven, additional, Ede, Nicholas, additional, Nixon, Bonnie, additional, and Good, Anthony J, additional

Published
2022
Full Text
View/download PDF

221. Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration.

Author

Takahashi, Hideaki, primary, Caughey, Bennett Adam, additional, Umemoto, Kumiko, additional, Green, Michelle, additional, Nakamura, Yoshiaki, additional, Datto, Michael, additional, Ueno, Makoto, additional, Walden, Daniel, additional, Esaki, Taito, additional, Oliver, Thomas, additional, Komatsu, Yoshito, additional, Mizuno, Nobumasa, additional, Oki, Eiji, additional, Taniguchi, Hiroya, additional, Bando, Hideaki, additional, Morizane, Chigusa, additional, Yoshino, Takayuki, additional, Strickler, John H, additional, Ikeda, Masafumi, additional, and Bekaii-Saab, Tanios S., additional

Published
2022
Full Text
View/download PDF

222. Universal genetic testing versus guideline-directed testing for hereditary cancer syndromes among traditionally underrepresented patients in a community oncology program.

Author

Jones, Jeremy Clifton, primary, Coston, Tucker, additional, Kunze, Katie, additional, Golafshar, Michael A., additional, Rao, Rohit, additional, Wysokinska, Ewa Maria, additional, Johnson, Elizabeth, additional, Esplin, Edward D., additional, Nussbaum, Robert Luke, additional, Heald, Brandie, additional, Klint, Margaret, additional, Barrus, Kathleen, additional, Bekaii-Saab, Tanios S., additional, Dronca, Roxana Stefania, additional, and Samadder, Jewel, additional

Published
2022
Full Text
View/download PDF

224. Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.

Author

Caughey, Bennett Adam, primary, Umemoto, Kumiko, additional, Green, Michelle, additional, Ikeda, Masafumi, additional, D'Anna, Rachel, additional, Ueno, Makoto, additional, Niedzwiecki, Donna, additional, Taniguchi, Hiroya, additional, Walden, Daniel, additional, Komatsu, Yoshito, additional, Zhou, Katherine I., additional, Esaki, Taito, additional, Ramaker, Ryne, additional, Denda, Tadamichi, additional, Datto, Michael, additional, Bando, Hideaki, additional, Bekaii-Saab, Tanios S., additional, Yoshino, Takayuki, additional, Strickler, John H, additional, and Nakamura, Yoshiaki, additional

Published
2022
Full Text
View/download PDF

225. KRAS wild-type pancreatic ductal adenocarcinoma: Molecular and therapeutic opportunities.

Author

Desai, Aakash, primary, Walden, Daniel, additional, Halfdanarson, Thorvardur Ragnar, additional, Alberts, Steven R, additional, McWilliams, Robert R., additional, Mahipal, Amit, additional, Ahn, Daniel H., additional, Babiker, Hani M., additional, Tella, Sri Harsha, additional, McGarrah, Patrick Walsh, additional, Kizilbash, Sani Haider, additional, Adjei, Alex A., additional, Bekaii-Saab, Tanios S., additional, and Ma, Wen Wee, additional

Published
2022
Full Text
View/download PDF

226. Responses to immune checkpoint inhibition among MSI-H pancreatic ductal adenocarcinoma: A multi-institutional case series.

Author

Coston, Tucker, primary, Starr, Jason S., additional, Sonbol, Bassam Bassam, additional, Babiker, Hani M., additional, Mahipal, Amit, additional, Chakrabarti, Sakti, additional, McWilliams, Robert R., additional, Bekaii-Saab, Tanios S., additional, Desai, Aakash, additional, Jones, Jeremy Clifton, additional, and Ma, Wen Wee, additional

Published
2022
Full Text
View/download PDF

227. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy

Author

Uson Junior, Pedro Luiz Serrano, primary, Majeed, Umair, additional, Yin, Jun, additional, Botrus, Gehan, additional, Sonbol, Mohamad Bassam, additional, Ahn, Daniel H., additional, Starr, Jason S., additional, Jones, Jeremy C., additional, Babiker, Hani, additional, Inabinett, Samantha R., additional, Wylie, Natasha, additional, Boyle, Ashton W.R., additional, Bekaii-Saab, Tanios S., additional, Gores, Gregory J., additional, Smoot, Rory, additional, Barrett, Michael, additional, Nagalo, Bolni, additional, Meurice, Nathalie, additional, Elliott, Natalie, additional, Petit, Joachim, additional, Zhou, Yumei, additional, Arora, Mansi, additional, Dumbauld, Chelsae, additional, Barro, Oumar, additional, Baker, Alexander, additional, Bogenberger, James, additional, Buetow, Kenneth, additional, Mansfield, Aaron, additional, Mody, Kabir, additional, and Borad, Mitesh J., additional

Published
2022
Full Text
View/download PDF

229. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.

Author

Javle, Milind, Javle, Milind, Lee, Sunyoung, Azad, Nilofer, Borad, Mitesh, Kate Kelley, Robin, Sivaraman, Smitha, Teschemaker, Anna, Chopra, Ishveen, Janjan, Nora, Parasuraman, Shreekant, Bekaii-Saab, Tanios, Javle, Milind, Javle, Milind, Lee, Sunyoung, Azad, Nilofer, Borad, Mitesh, Kate Kelley, Robin, Sivaraman, Smitha, Teschemaker, Anna, Chopra, Ishveen, Janjan, Nora, Parasuraman, Shreekant, and Bekaii-Saab, Tanios

Abstract

BACKGROUND: Previous studies report increasing cholangiocarcinoma (CCA) incidence up to 2015. This contemporary retrospective analysis of CCA incidence and mortality in the US from 2001-2017 assessed whether CCA incidence continued to increase beyond 2015. PATIENTS AND METHODS: Patients (≥18 years) with CCA were identified in the National Cancer Institute Surveillance, Epidemiology, and End Results 18 cancer registry (International Classification of Disease for Oncology [ICD-O]-3 codes: intrahepatic [iCCA], C221; extrahepatic [eCCA], C240, C241, C249). Cancer of unknown primary (CUP) cases were identified (ICD-O-3: C809; 8140/2, 8140/3, 8141/3, 8143/3, 8147/3) because of potential misclassification as iCCA. RESULTS: Forty-thousand-and-thirty CCA cases (iCCA, n=13,174; eCCA, n=26,821; iCCA and eCCA, n=35) and 32,980 CUP cases were analyzed. From 2001-2017, CCA, iCCA, and eCCA incidence (per 100 000 person-years) increased 43.8% (3.08 to 4.43), 148.8% (0.80 to 1.99), and 7.5% (2.28 to 2.45), respectively. In contrast, CUP incidence decreased 54.4% (4.65 to 2.12). CCA incidence increased with age, with greatest increase among younger patients (18-44 years, 81.0%). Median overall survival from diagnosis was 8, 6, 9, and 2 months for CCA, iCCA, eCCA, and CUP. From 2001-2016, annual mortality rate declined for iCCA (57.1% to 41.2%) and generally remained stable for eCCA (40.9% to 37.0%) and for CUP (64.3% to 68.6%). CONCLUSIONS: CCA incidence continued to increase from 2001-2017, with greater increase in iCCA versus eCCA, whereas CUP incidence decreased. The divergent CUP versus iCCA incidence trends, with overall greater absolute change in iCCA incidence, provide evidence for a true increase in iCCA incidence that may not be wholly attributable to CUP reclassification.

Published
2022

230. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial

Author

Tempero, Margaret A., Pelzer, Uwe, O'Reilly, Eileen M., Winter, Jordan, Oh, Do-Youn, Li, Chung-Pin, Tortora, Giampaolo, Chang, Heung-Moon, Lopez, Charles D., Bekaii-Saab, Tanios, Ko, Andrew H., Santoro, Armando, Park, Joon Oh, Noel, Marcus S., Frassineti, Giovanni Luca, Shan, Yan-Shen, Dean, Andrew, Riess, Hanno, Van Cutsem, Eric, Berlin, Jordan, Philip, Philip, Moore, Malcolm, Goldstein, David, Tabernero, Josep, Li, Mingyu, Ferrara, Stefano, Le Bruchec, Yvan, Zhang, George, Lu, Brian, Biankin, Andrew V., Reni, Michele, Tempero, Margaret A., Pelzer, Uwe, O'Reilly, Eileen M., Winter, Jordan, Oh, Do-Youn, Li, Chung-Pin, Tortora, Giampaolo, Chang, Heung-Moon, Lopez, Charles D., Bekaii-Saab, Tanios, Ko, Andrew H., Santoro, Armando, Park, Joon Oh, Noel, Marcus S., Frassineti, Giovanni Luca, Shan, Yan-Shen, Dean, Andrew, Riess, Hanno, Van Cutsem, Eric, Berlin, Jordan, Philip, Philip, Moore, Malcolm, Goldstein, David, Tabernero, Josep, Li, Mingyu, Ferrara, Stefano, Le Bruchec, Yvan, Zhang, George, Lu, Brian, Biankin, Andrew V., and Reni, Michele

Abstract

PURPOSE This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430). METHODS We assigned 866 treatment-naive patients with pancreatic ductal adenocarcinoma to nab-paclitaxel (125 mg/m2) + gemcitabine (1,000 mg/m2) or gemcitabine alone to one 30-40 infusion on days 1, 8, and 15 of six 28-day cycles. The primary end point was independently assessed disease-free survival (DFS). Additional end points included investigator-assessed DFS, overall survival (OS), and safety. RESULTS Two hundred eighty-seven of 432 patients and 310 of 434 patients completed nab-paclitaxel + gemcitabine and gemcitabine treatment, respectively. At primary data cutoff (December 31, 2018; median follow-up, 38.5 [interquartile range [IQR], 33.8-43 months), the median independently assessed DFS was 19.4 (nab-paclitaxel + gemcitabine) versus 18.8 months (gemcitabine; hazard ratio [HR], 0.88; 95% CI, 0.729 to 1.063; P = .18). The median investigator-assessed DFS was 16.6 (IQR, 8.4-47.0) and 13.7 (IQR, 8.3-44.1) months, respectively (HR, 0.82; 95% CI, 0.694 to 0.965; P = .02). The median OS (427 events; 68% mature) was 40.5 (IQR, 20.7 to not reached) and 36.2 (IQR, 17.7-53.3) months, respectively (HR, 0.82; 95% CI, 0.680 to 0.996; P = .045). At a 16-month follow-up (cutoff, April 3, 2020; median follow-up, 51.4 months [IQR, 47.0-57.0]), the median OS (511 events; 81% mature) was 41.8 (nab-paclitaxel + gemcitabine) versus 37.7 months (gemcitabine; HR, 0.82; 95% CI, 0.687 to 0.973; P = .0232). At the 5-year follow-up (cutoff, April 9, 2021; median follow-up, 63.2 months [IQR, 60.1-68.7]), the median OS (555 events; 88% mature) was 41.8 versus 37.7 months, respectively (HR, 0.80; 95% CI, 0.678 to 0.947; P = .0091). Eighty-six percent (nab-paclitaxel + gemcitabine) and 68% (gemcitabine) of patients experienced grade ≥ 3 treatment-emergent adve

Published
2022

232. Understanding Suboptimal Response to Immune Checkpoint Inhibitors.

Author

Zhu, Mojun, Zhang, Henan, Pedersen, Katrina S., Foster, Nathan R., Jaszewski, Brandy L., Liu, Xin, Hirdler, Jacob B., An, Zesheng, Bekaii‐Saab, Tanios S., Halfdanarson, Thorvardur R., Boland, Patrick M., Yan, Yiyi, Hubbard, Joleen H., Ma, Wen Wee, Yoon, Harry H., Revzin, Alexander, Fernandez‐Zapico, Martin E., Overman, Michael J., McWilliams, Robert R., and Dong, Haidong

Subjects
IMMUNE checkpoint inhibitors, SMALL intestine cancer, PROGRAMMED cell death 1 receptors, IMMUNE response, CLINICAL indications, TREATMENT effectiveness
Abstract

Immune checkpoint inhibitors (ICIs), as a novel class of anticancer therapy, can be more efficacious and less toxic than chemotherapy, but their clinical success is confined to certain tumor types. Elucidating their targets, mechanisms and scope of action, and potential synergism with chemotherapy and/or targeted therapies are critical to widen their clinical indications. Treatment response to an ICI targeting programmed death‐1 (anti‐PD‐1) is sought to be understood here by conducting a preplanned correlative analysis of a phase II clinical trial in patients with small bowel adenocarcinoma (SBA). The cytolytic capacity of circulating immune cells in cancer patients using a novel ex vivo cytotoxicity assay is evaluated, and the utility of circulating biomarkers is investigated to predict and monitor the treatment effect of anti‐PD‐1. Baseline expression of Bim and NKG7 and upregulation of CX3CR1 in circulating T cells are associated with the clinical benefit of anti‐PD‐1 in patients with SBA. Overall, these findings suggest that the frequency and cytolytic capacity of circulating, effector immune cells may differentiate clinical response to ICIs, providing a strong rationale to support immune monitoring using patient peripheral blood. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

242. Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Author

Zhu, Mojun, primary, Chen, Chunhua, additional, Foster, Nathan R., additional, Hartley, Christopher, additional, Mounajjed, Taofic, additional, Salomao, Marcela A., additional, Fruth, Briant F., additional, Beamer, Staci E., additional, Kim, Yohan, additional, Harrington, Susan M., additional, Pitot, Henry C., additional, Sanhueza, Cristobal T., additional, Feng, Yening, additional, Herrmann, Joerg, additional, McWilliams, Robert R., additional, Lucien, Fabrice, additional, Huang, Bing Q., additional, Ma, Wen Wee, additional, Bekaii-Saab, Tanios S., additional, Dong, Haidong, additional, Wigle, Dennis, additional, Ahn, Daniel H., additional, Hallemeier, Chris L., additional, Blackmon, Shanda, additional, and Yoon, Harry H., additional

Published
2022
Full Text
View/download PDF

246. Understanding Suboptimal Response to Immune Checkpoint Inhibitors

Author

Zhu, Mojun, primary, Zhang, Henan, additional, Pedersen, Katrina S., additional, Foster, Nathan R., additional, Jaszewski, Brandy L., additional, Liu, Xin, additional, Hirdler, Jacob B., additional, An, Zesheng, additional, Bekaii‐Saab, Tanios S., additional, Halfdanarson, Thorvardur R., additional, Boland, Patrick M., additional, Yan, Yiyi, additional, Hubbard, Joleen H., additional, Ma, Wen Wee, additional, Yoon, Harry H., additional, Revzin, Alexander, additional, Fernandez‐Zapico, Martin E., additional, Overman, Michael J., additional, McWilliams, Robert R., additional, and Dong, Haidong, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results